Abstract Neurobiomarkers measured in peripheral blood can supplement management strategies following traumatic brain injury (TBI). Dual-assay of glial fibrillary acid protein (GFAP) and ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1) is FDA-approved to inform a decision threshold approach (GFAP > 30 µg.L− 1 and/or UCHL1 > 360 µg.L− 1) for post-TBI neuroimaging.
Todd Leckie
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Todd
Contact Todd, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack